Published in J Virol on June 01, 2003
Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin Vaccine Immunol (2006) 2.01
Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol (2010) 1.96
Protective CD8 T cells against Plasmodium liver stages: immunobiology of an 'unnatural' immune response. Immunol Rev (2008) 1.64
Vaccine efficacy against malaria by the combination of porcine parvovirus-like particles and vaccinia virus vectors expressing CS of Plasmodium. PLoS One (2012) 1.43
Induction of cellular immune responses to simian immunodeficiency virus gag by two recombinant negative-strand RNA virus vectors. J Virol (2004) 1.12
Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization. Virology (2008) 1.07
Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines. Vaccine (2007) 1.04
The evolution of poxvirus vaccines. Viruses (2015) 1.02
Evaluation of recombinant influenza virus-simian immunodeficiency virus vaccines in macaques. J Virol (2009) 0.96
The influence of delivery vectors on HIV vaccine efficacy. Front Microbiol (2014) 0.92
Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS. J Virol (2010) 0.91
Mucosal and systemic immune responses to a human immunodeficiency virus type 1 epitope induced upon vaginal infection with a recombinant influenza A virus. J Virol (2004) 0.90
IL-12 and GM-CSF in DNA/MVA immunizations against HIV-1 CRF12_BF Nef induced T-cell responses with an enhanced magnitude, breadth and quality. PLoS One (2012) 0.85
Vaginal immunization to elicit primary T-cell activation and dissemination. PLoS One (2013) 0.85
Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes. Expert Opin Biol Ther (2010) 0.84
Induction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy. Front Immunol (2014) 0.81
Role of cell signaling in poxvirus-mediated foreign gene expression in mammalian cells. Vaccine (2009) 0.79
Use of Reporter Genes in the Generation of Vaccinia Virus-Derived Vectors. Viruses (2016) 0.75
Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science (1998) 12.81
Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med (1996) 5.35
[The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]. Zentralbl Bakteriol B (1978) 2.92
Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. Proc Natl Acad Sci U S A (1993) 2.44
Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infect Immun (1997) 2.05
The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today (2000) 2.03
Vaccination strategies for mucosal immune responses. Clin Microbiol Rev (2001) 1.98
Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine (2002) 1.97
Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer. Proc Natl Acad Sci U S A (1998) 1.74
Induction of CD8+ T cells using heterologous prime-boost immunisation strategies. Immunol Rev (1999) 1.72
Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc Natl Acad Sci U S A (1999) 1.63
Prime-boost immunization strategies for infectious diseases. Curr Opin Mol Ther (2002) 1.57
Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A). J Immunol (1996) 1.46
Vaginal transmission of human immunodeficiency virus (HIV) to a chimpanzee. J Infect Dis (1986) 1.38
Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. J Virol (1996) 1.33
Cytotoxic T lymphocytes specific for the simian immunodeficiency virus. Immunol Rev (1999) 1.23
Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector. J Virol (2000) 1.22
Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA. Vaccine (1999) 1.14
Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts. J Immunol (1999) 1.13
IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner. J Immunol (1999) 1.08
A striking property of recombinant poxviruses: efficient inducers of in vivo expansion of primed CD8(+) T cells. Virology (2001) 1.07
Tissue distribution of the Ankara strain of vaccinia virus (MVA) after mucosal or systemic administration. Arch Virol (2003) 1.06
Chimeric influenza virus replicating predominantly in the murine upper respiratory tract induces local immune responses against human immunodeficiency virus type 1 in the genital tract. J Infect Dis (1998) 1.03
Development of novel influenza virus vaccines and vectors. J Infect Dis (1997) 1.03
[Experiences with immunization against orthopox viruses of humans and animals using vaccine strain MVA]. Berl Munch Tierarztl Wochenschr (1994) 1.03
A rational basis for mucosal vaccination against HIV infection. Immunol Rev (1999) 1.02
Recombinant viruses as a tool for therapeutic vaccination against human cancers. Immunol Lett (2000) 0.99
Targeted lymph node immunization can protect cats from a mucosal challenge with feline immunodeficiency virus. Vaccine (2001) 0.94
Enhanced CD8+ T cell response to HIV-1 env by combined immunization with influenza and vaccinia virus recombinants. Vaccine (1999) 0.93
The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys. Vaccine (1998) 0.93
Heterologous prime-boost vaccination strategies for HIV-1: augmenting cellular immune responses. Curr Opin Investig Drugs (2002) 0.91
Homing of mononuclear cells from iliac lymph nodes to the genital and rectal mucosa in non-human primates. Eur J Immunol (1998) 0.86
Towards a new generation of vaccines: the cytokine IL-12 as an adjuvant to enhance cellular immune responses to pathogens during prime-booster vaccination regimens. Histol Histopathol (2001) 0.85
DNA-based vaccines for malaria: a heterologous prime-boost immunisation strategy. Dev Biol (Basel) (2000) 0.85
Protective CD8+ T cell responses against the pre-erythrocytic stages of malaria parasites: an overview. Mem Inst Oswaldo Cruz (2001) 0.77
Vehicles for genetic vaccines against human immunodeficiency virus: induction of T cell-mediated immune responses. Curr Mol Med (2001) 0.76
Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science (2005) 17.19
A two-amino acid change in the hemagglutinin of the 1918 influenza virus abolishes transmission. Science (2007) 8.38
Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. J Virol (2007) 7.18
Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. Nature (2006) 6.46
Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity (2013) 5.47
Human host factors required for influenza virus replication. Nature (2010) 5.28
Programming the magnitude and persistence of antibody responses with innate immunity. Nature (2011) 5.18
Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe (2009) 5.12
Inhibition of interferon signaling by dengue virus. Proc Natl Acad Sci U S A (2003) 5.05
Inhibition of retinoic acid-inducible gene I-mediated induction of beta interferon by the NS1 protein of influenza A virus. J Virol (2006) 4.88
H5N1 and 1918 pandemic influenza virus infection results in early and excessive infiltration of macrophages and neutrophils in the lungs of mice. PLoS Pathog (2008) 4.79
The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol (2003) 4.73
A single amino acid substitution in 1918 influenza virus hemagglutinin changes receptor binding specificity. J Virol (2005) 4.71
The guinea pig as a transmission model for human influenza viruses. Proc Natl Acad Sci U S A (2006) 4.58
Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins. J Virol (2003) 4.45
Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. J Virol (2005) 4.31
Cellular transcriptional profiling in influenza A virus-infected lung epithelial cells: the role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza. Proc Natl Acad Sci U S A (2002) 4.26
Attenuation of equine influenza viruses through truncations of the NS1 protein. J Virol (2005) 4.16
Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio (2010) 4.15
Ovarian tumor domain-containing viral proteases evade ubiquitin- and ISG15-dependent innate immune responses. Cell Host Microbe (2007) 4.14
Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus. Proc Natl Acad Sci U S A (2009) 4.12
Pathogenicity and immunogenicity of influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci U S A (2004) 4.00
IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proc Natl Acad Sci U S A (2007) 3.98
Human HA and polymerase subunit PB2 proteins confer transmission of an avian influenza virus through the air. Proc Natl Acad Sci U S A (2009) 3.91
Interferon antagonist proteins of influenza and vaccinia viruses are suppressors of RNA silencing. Proc Natl Acad Sci U S A (2004) 3.85
Matrix protein 2 of influenza A virus blocks autophagosome fusion with lysosomes. Cell Host Microbe (2009) 3.79
Gain-of-function experiments on H7N9. Science (2013) 3.67
Multiple anti-interferon actions of the influenza A virus NS1 protein. J Virol (2007) 3.53
Influenza virus PB1-F2 protein induces cell death through mitochondrial ANT3 and VDAC1. PLoS Pathog (2005) 3.44
A recombinant influenza A virus expressing an RNA-binding-defective NS1 protein induces high levels of beta interferon and is attenuated in mice. J Virol (2003) 3.44
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med (2008) 3.42
Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci U S A (2010) 3.24
Analysis of in vivo dynamics of influenza virus infection in mice using a GFP reporter virus. Proc Natl Acad Sci U S A (2010) 3.17
Multiple functions of the IKK-related kinase IKKepsilon in interferon-mediated antiviral immunity. Science (2007) 3.16
Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines. PLoS Pathog (2010) 3.08
Influenza research database: an integrated bioinformatics resource for influenza research and surveillance. Influenza Other Respir Viruses (2012) 3.04
Influenza A viruses: new research developments. Nat Rev Microbiol (2011) 3.00
Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc Natl Acad Sci U S A (2012) 2.96
Influenza virus evades innate and adaptive immunity via the NS1 protein. J Virol (2006) 2.94
Mutations in the NS1 protein of swine influenza virus impair anti-interferon activity and confer attenuation in pigs. J Virol (2005) 2.88
Preference of RIG-I for short viral RNA molecules in infected cells revealed by next-generation sequencing. Proc Natl Acad Sci U S A (2010) 2.81
Single gene reassortants identify a critical role for PB1, HA, and NA in the high virulence of the 1918 pandemic influenza virus. Proc Natl Acad Sci U S A (2008) 2.72
Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza. J Virol (2008) 2.71
Newcastle disease virus V protein is a determinant of host range restriction. J Virol (2003) 2.61
Inhibition of the type I interferon response by the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol (2006) 2.61
NS5 of dengue virus mediates STAT2 binding and degradation. J Virol (2009) 2.42
Replication fitness determines high virulence of influenza A virus in mice carrying functional Mx1 resistance gene. Proc Natl Acad Sci U S A (2007) 2.33
Avian flu: Gain-of-function experiments on H7N9. Nature (2013) 2.32
Pause on avian flu transmission research. Science (2012) 2.24
Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog (2009) 2.24
Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease. Proc Natl Acad Sci U S A (2006) 2.23
Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci U S A (2002) 2.21
Identification of cellular interaction partners of the influenza virus ribonucleoprotein complex and polymerase complex using proteomic-based approaches. J Proteome Res (2007) 2.21
Suppression of the antiviral response by an influenza histone mimic. Nature (2012) 2.18
Virulence-associated substitution D222G in the hemagglutinin of 2009 pandemic influenza A(H1N1) virus affects receptor binding. J Virol (2010) 2.17
Viral tricks to grid-lock the type I interferon system. Curr Opin Microbiol (2010) 2.17
The influenza A virus NS1 protein inhibits activation of Jun N-terminal kinase and AP-1 transcription factors. J Virol (2002) 2.14
Transmission of influenza virus via aerosols and fomites in the guinea pig model. J Infect Dis (2009) 2.12
Type I interferon induction pathway, but not released interferon, participates in the maturation of dendritic cells induced by negative-strand RNA viruses. J Infect Dis (2003) 2.05
PB1-F2 expression by the 2009 pandemic H1N1 influenza virus has minimal impact on virulence in animal models. J Virol (2010) 2.01
Nipah virus V and W proteins have a common STAT1-binding domain yet inhibit STAT1 activation from the cytoplasmic and nuclear compartments, respectively. J Virol (2004) 1.98
Cellular gene expression survey of vaccinia virus infection of human HeLa cells. J Virol (2003) 1.97
Inhibition of Beta interferon induction by severe acute respiratory syndrome coronavirus suggests a two-step model for activation of interferon regulatory factor 3. J Virol (2005) 1.96
Incoming RNA virus nucleocapsids containing a 5'-triphosphorylated genome activate RIG-I and antiviral signaling. Cell Host Microbe (2013) 1.95
Differential inhibition of type I interferon induction by arenavirus nucleoproteins. J Virol (2007) 1.95
Endoplasmic reticulum-Golgi intermediate compartment membranes and vimentin filaments participate in vaccinia virus assembly. J Virol (2002) 1.94
Translational resistance of late alphavirus mRNA to eIF2alpha phosphorylation: a strategy to overcome the antiviral effect of protein kinase PKR. Genes Dev (2006) 1.94
The NS5 protein of the virulent West Nile virus NY99 strain is a potent antagonist of type I interferon-mediated JAK-STAT signaling. J Virol (2010) 1.94
The Mx1 gene protects mice against the pandemic 1918 and highly lethal human H5N1 influenza viruses. J Virol (2007) 1.93
Reverse genetics studies on the filamentous morphology of influenza A virus. J Gen Virol (2003) 1.92
Transmission of pandemic H1N1 influenza virus and impact of prior exposure to seasonal strains or interferon treatment. J Virol (2010) 1.92
Virulence determinants of pandemic influenza viruses. J Clin Invest (2011) 1.87
Complete-proteome mapping of human influenza A adaptive mutations: implications for human transmissibility of zoonotic strains. PLoS One (2010) 1.87
Protective immunity to lethal challenge of the 1918 pandemic influenza virus by vaccination. Proc Natl Acad Sci U S A (2006) 1.83
The M segment of the 2009 new pandemic H1N1 influenza virus is critical for its high transmission efficiency in the guinea pig model. J Virol (2011) 1.82
Functional replacement of the carboxy-terminal two-thirds of the influenza A virus NS1 protein with short heterologous dimerization domains. J Virol (2002) 1.81
Inefficient control of host gene expression by the 2009 pandemic H1N1 influenza A virus NS1 protein. J Virol (2010) 1.81
Influenza A virus-generated small RNAs regulate the switch from transcription to replication. Proc Natl Acad Sci U S A (2010) 1.77
Integration of clinical data, pathology, and cDNA microarrays in influenza virus-infected pigtailed macaques (Macaca nemestrina). J Virol (2004) 1.77
Influenza vaccines: present and future. J Clin Invest (2002) 1.74
Mice lacking the ISG15 E1 enzyme UbE1L demonstrate increased susceptibility to both mouse-adapted and non-mouse-adapted influenza B virus infection. J Virol (2008) 1.73
Viruses and the type I interferon antiviral system: induction and evasion. Int Rev Immunol (2002) 1.73
Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector. J Virol (2006) 1.73
Oseltamivir-resistant variants of the 2009 pandemic H1N1 influenza A virus are not attenuated in the guinea pig and ferret transmission models. J Virol (2010) 1.72
Transcriptional role of p53 in interferon-mediated antiviral immunity. J Exp Med (2008) 1.72
Pause on avian flu transmission studies. Nature (2012) 1.71
The E3-ligase TRIM family of proteins regulates signaling pathways triggered by innate immune pattern-recognition receptors. Immunity (2013) 1.69
Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC. J Virol (2007) 1.68
The interferon system and vaccinia virus evasion mechanisms. J Interferon Cytokine Res (2009) 1.67
Dissection of the influenza A virus endocytic routes reveals macropinocytosis as an alternative entry pathway. PLoS Pathog (2011) 1.66
Microarray analysis reveals characteristic changes of host cell gene expression in response to attenuated modified vaccinia virus Ankara infection of human HeLa cells. J Virol (2004) 1.65
Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach. J Virol (2008) 1.64
Effects of influenza A virus NS1 protein on protein expression: the NS1 protein enhances translation and is not required for shutoff of host protein synthesis. J Virol (2002) 1.63
Influenza A virus strains differ in sensitivity to the antiviral action of Mx-GTPase. J Virol (2008) 1.62
Identification of amino acid residues critical for the anti-interferon activity of the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol (2009) 1.61
The influenza virus protein PB1-F2 inhibits the induction of type I interferon at the level of the MAVS adaptor protein. PLoS Pathog (2011) 1.60
Detection of respiratory viruses and subtype identification of influenza A viruses by GreeneChipResp oligonucleotide microarray. J Clin Microbiol (2007) 1.59